Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.30 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3475308 | 0.80 | MAP4K4 (0.46) | SCN9AMAP4K4SCN10ACNR1CNR2 | |
| SCHEMBL3475806 | 0.72 | SCN9A (0.37) | SCN9AMAP4K4SCN10ACNR1CNR2 | |
| SCHEMBL27913818 | 0.67 | KDM4E (0.39) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL3475808 | 0.67 | SCN9A (0.35) | SCN9AMAP4K4SCN10ACNR1CNR2 | |
| SCHEMBL31292391 | 0.66 | CYP2C19 (0.46) | SCN9ACNR2 | |
| SCHEMBL12093558 | 0.64 | NNMT (0.44) | — | |
| SCHEMBL3474160 | 0.63 | HSD11B1 (0.52) | CNR1CNR2HSD11B1NR3C1KCNH2 | |
| SCHEMBL16326512 | 0.62 | KDM4E (0.45) | MAP4K4CNR1CNR2HSD11B1 | |
| SCHEMBL3474425 | 0.62 | MAP4K4 (0.48) | MAP4K4 | |
| SCHEMBL31292214 | 0.62 | DGAT1 (0.39) | SCN9AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754188-B2 | Radiolabeled cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1641493-A4 | RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20060115425-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2006-06-01 | — | — | US | disclosed |
| EP-1641493-A1 | RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005009479-A1 | RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060115425-A1 | Substituted amides | CNR1, CNR2, FAAH | SCN9A 1970/4885MAP4K4 2487/4885SCN10A 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.